期刊
BREAST CANCER RESEARCH AND TREATMENT
卷 114, 期 2, 页码 223-232出版社
SPRINGER
DOI: 10.1007/s10549-008-0002-9
关键词
Breast cancer; Mammaglobin; Minimal residual disease
类别
资金
- Fundacao para a Ciencia e Tecnologia [PRAXIS/P/SAU/14037/1998]
- Liga Portuguesa Contra o Cancro
Introduction Human mammaglobin (hMAM) mRNA is a sensitive and specific marker of breast cancer cells. We evaluated if hMAM mRNA detection in serial peripheral blood samples from non-metastatic breast cancer patients predicts for disease recurrence. Methods Patients scheduled for adjuvant or neoadjuvant chemotherapy were eligible. Serial blood samples were collected up to 5 years, the first before (neo) adjuvant chemotherapy. hMAM gene expression was analysed by RT-PCR. Specificity was evaluated in blood samples from healthy volunteers. A total of 321 patients were included. Results The incidence of pre-chemotherapy hMAM-positive samples was similar in patients who latter experienced cancer recurrence (22.4%) and those who remained disease-free (17.9%; P = 0.46). Similarly, the mean number of positive follow-up samples was similar in both groups (0.15 +/- 0.22 and 0.13 +/- 013; P = 0.29). Furthermore, there was no difference in disease-free (P = 0.63) or overall survival (P = 0.57) in patients with and without positive baseline samples or between patients whose follow-up samples were always hMAM negative and those with at least one positive sample. Multivariate survival analysis confirmed that hMAM mRNA detection before or after (neo) adjuvant chemotherapy was not predictive of recurrence. Discussion There is no evidence that hMAM mRNA detection at diagnosis or during follow-up predicts for breast cancer recurrence.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据